Logo 1 Logo 2

Repositioning Candidate Details

Candidate ID: R0201
Source ID: DB00701
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Amprenavir
Synonyms:
Molecular Formula: C25H35N3O6S
SMILES: CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
Structure:
DrugBank Description: Amprenavir is a protease inhibitor used to treat HIV infection.
CAS Number: 161814-49-9
Molecular Weight: 505.627
DrugBank Indication: For the treatment of HIV-1 infection in combination with other antiretroviral agents.
DrugBank Pharmacology: Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
DrugBank MoA: Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Targets: Human immunodeficiency virus type 1 protease
Inclusion Criteria: